Carlsmed, a spine medtech company, launched its initial public offering of 6.7 million shares of common stock, according to a June 15 news release.
Common stock price is expected to be between $14 and $16 per share, and the company applied to be listed on the Nasdaq Global Select Market.
Carlsmed is behind aprevo personalized spine implants. The company filed for the IPO in June, and BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler are the joint lead book-running managers and representatives.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.